Protara Therapeutics, Inc.

DB:1KPA Stock Report

Market Cap: €51.2m

Protara Therapeutics Valuation

Is 1KPA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1KPA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 1KPA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 1KPA's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1KPA?

Key metric: As 1KPA is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 1KPA. This is calculated by dividing 1KPA's market cap by their current book value.
What is 1KPA's PB Ratio?
PB Ratio0.7x
BookUS$81.79m
Market CapUS$53.64m

Price to Book Ratio vs Peers

How does 1KPA's PB Ratio compare to its peers?

The above table shows the PB ratio for 1KPA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average12.7x
VSC 4SC
45.8xn/a€51.9m
2INV 2invest
1xn/a€62.7m
MDG1 Medigene
0.9x11.0%€17.4m
HPHA Heidelberg Pharma
3x-33.0%€105.8m
1KPA Protara Therapeutics
0.7x-4.7%€53.6m

Price-To-Book vs Peers: 1KPA is good value based on its Price-To-Book Ratio (0.7x) compared to the peer average (12.7x).


Price to Book Ratio vs Industry

How does 1KPA's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
1KPA 0.7xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 1KPA is good value based on its Price-To-Book Ratio (0.7x) compared to the European Biotechs industry average (2.4x).


Price to Book Ratio vs Fair Ratio

What is 1KPA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1KPA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 1KPA's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1KPA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€2.76
€28.06
+916.7%
40.6%€47.56€19.02n/a4
Nov ’25€2.20
€23.92
+987.1%
46.9%€45.30€12.68n/a5
Oct ’25€1.61
€23.92
+1,385.5%
46.9%€45.30€12.68n/a5
Sep ’25€1.79
€24.18
+1,250.8%
46.9%€45.80€12.82n/a5
Aug ’25€2.04
€25.82
+1,165.9%
43.9%€46.45€13.00n/a5
Jul ’25€1.95
€25.82
+1,224.3%
43.9%€46.45€13.00n/a5
Jun ’25€2.64
€25.82
+878.2%
43.9%€46.45€13.00n/a5
May ’25€2.86
€26.10
+812.5%
43.9%€46.94€13.14n/a5
Apr ’25€3.62
€28.54
+688.4%
33.7%€46.64€20.52n/a5
Mar ’25€4.20
€28.54
+579.5%
33.7%€46.64€20.52n/a5
Feb ’25€2.34
€28.54
+1,119.7%
33.7%€46.64€20.52n/a5
Jan ’25€1.69
€28.54
+1,588.8%
33.7%€46.64€20.52n/a5
Dec ’24€1.29
€28.54
+2,112.5%
33.7%€46.64€20.52n/a5
Nov ’24€1.05
€28.70
+2,633.0%
32.1%€45.70€20.11€2.205
Oct ’24€1.51
€28.70
+1,800.4%
32.1%€45.70€20.11€1.615
Sep ’24€1.93
€28.70
+1,386.9%
32.1%€45.70€20.11€1.795
Aug ’24€2.28
€28.55
+1,152.1%
32.1%€45.46€20.00€2.045
Jul ’24€1.98
€30.62
+1,446.5%
29.5%€45.37€20.87€1.954
Jun ’24€2.58
€30.62
+1,086.9%
29.5%€45.37€20.87€2.644
May ’24€2.86
€30.63
+970.9%
29.5%€45.38€20.87€2.864
Apr ’24€2.80
€31.90
+1,039.2%
29.5%€47.26€21.74€3.624
Mar ’24€3.28
€33.67
+926.5%
29.5%€49.88€22.94€4.204
Feb ’24€2.96
€33.67
+1,037.5%
29.5%€49.88€22.94€2.344
Jan ’24€2.56
€33.67
+1,215.2%
29.5%€49.88€22.94€1.694
Dec ’23€3.30
€33.67
+920.3%
29.5%€49.88€22.94€1.294
Nov ’23€3.06
€32.72
+969.4%
29.5%€48.48€22.30€1.054

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies